Sean He Partner NOVO HOLDINGS

Sean joined Novo Holdings in May 2022 as Partner and Head of China.

He has 10 years of healthcare investment experience.  Prior to Novo Holdings, Sean was employed as a Principal at Advent International, leading healthcare investing in China. Prior to Advent International, he worked at Warburg Pincus, where he spent five years focusing on investment in healthcare primarily in China and other key Asia markets.  Sean started his investing career at CITIC Capital, a control focused private equity firm in China.  Before investing, Sean worked in the investment banking division at UBS.

Sean holds a dual BA in English Literature and Economics from Beijing Foreign Studies University.

Meng Jiang Senior Managing Director and Head of Venture CBC GROUP

Meng has over 18 years of investment, M&A and investment banking experience. She has been at CBC Group since the beginning in early 2014, and has led investments in the pharmaceutical sector, including CMAB, I-MAB, and Innovent, among others. Meng spearheaded the launch of the firm’s Venture Capital strategy, which she currently heads.

Prior to CBC Group, Meng was most recently Director and COO at Far East Horizon’s Investments Group where she was responsible for department operations, risk management, and establishing and implementing budgets. For two years, Meng led teams on M&A and minority healthcare services investments. Prior to joining Far East Horizon, Meng was Managing Director at ARC China, where she established its China operations and headed various investments across multiple sectors. Before her time at ARC China, Meng was an Associate Director at Business Development Asia in Shanghai where she executed numerous joint ventures, acquisition and divestiture transactions in the chemical, consumer, and manufacturing sectors in China and Japan. Meng started her career at UBS Investment Bank in New York, where she worked on origination and execution of M&A, IPO, Debt and Equity issuances.

Meng graduated with Honours in Economics and Political Science from Wellesley College. 

James Huang Founding Managing Partner PANACEA VENTURE

James Huang is Founding Managing Partner of Panacea Healthcare Venture Capital (RMB 870m Fund & USD180.5m Fund). He has devoted his passion diligence、 intelligence and loyalty into life science and investment industry over 30 years. He is a successful entrepreneur, investor and an opinion leader in Venture Capital healthcare sector in China. Panacea Venture is focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Since its inception in 2018, Panacea has three portfolios listed and five more submitted IPO application. Panacea is currently raising its USD Fund II with a target fund size of USD 250 million. James Huang is also managing partner of Kleiner Perkins Caufield & Byers China. He joined the firm in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 15 investments in China since 2007. Prior to that, James was a Managing Partner at Vivo Ventures, a Venture Capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). James is Chairman of Board at Kindstar Global, JHL Biotech and XW Laboratory and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, CASI and Omni Pharmaceuticals. James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

王 一青 亚太区执行编辑 MERGERMARKET

Yiqing Wang is the Managing Editor for M&A and ECM, APAC, at Mergermarket. Ms. Wang is leading a team of dedicated journalists across APAC regions to cover PE/VC fundraising, M&A transactions, PE buyouts and exits,etc. 

She has been an investigative M&A reporter and researcher since 2009, writing industry news ranging from healthcare, new energy and financial service, etc. 

Ms. Wang achieved her master's degree of multilingual multicultural studies from New York University.

Alex Shum Managing Director TPG NEWQUEST

沈朝力先生是新程投资大中华地区董事总经理。沈先生于2011年加入新程投资，主要负责搜寻、评估和管理新程在大中华地区的投资项目。沈先生领导新程投资中国投资团队，专注于复杂的GP主导S交易方案，并且在PEVC直投领域也有着丰富的实操经验，在企业投后管理有着资深能力和很多成功的退出案例，他拥有超过十五年的金融领域工作经验，主要在投资、融资、并购和企业咨询。

在加入新程投资前，沈先生于瑞信香港的投资银行部担任经理，主要负责企业融资和股权股本市场。

沈先生本科毕业于美国杜克大学，攻读经济学学位。

戚 舒婷 合伙人 汉坤律师事务所

业务领域 

• 私募股权和风险投资 

• 兼并和收购 

• 外商直接投资 

• 一般公司事务 

工作经历 

在加入汉坤律师事务所之前，戚舒婷女士在美国凯易律师事务所(Kirkland & Ellis)担任合伙人，并有超过14年的从业经验。戚舒婷女士代表众多私募股权基金及战略投资者进行类型广泛的商业交易，在兼并收购、控股权收购、成长股权投资、退出及分拆交易、合资企业、外商直接投资及常规公司业务方面均具备丰富经验。戚舒婷女士同时代表中国公司开展境外投资和其他境外融资项目。 

戚舒婷女士服务的行业领域广泛，包括TMT、医疗、教育、金融、工业制造、零售、物流等众多行业。 

教育背景 

2012年获美国哈佛大学法学硕士学位；2008年获复旦大学法学硕士学位；2005年获南京大学法学本科学位。 

执业资格 

美国纽约州律师执业资格 

中华人民共和国法律职业资格 

工作语言 

中文、英文 

Yunyan Sang Director LEXINGTON PARTNERS

Yunyan Sang is a Director of Lexington Partners primarily engaged in the evaluation of secondary purchases of non-U.S. private equity and alternative investments. 

Prior to joining Lexington in 2015, Ms. Sang was an analyst in investment banking at Morgan Stanley Asia. Ms. Sang graduated from Yale University with a BA in economics.

Jolie Chow Managing Director PJT PARTNERS

Jolie Chow is a Managing Director at PJT Partners and Asia head of PJT Park Hill’s Secondary Advisory Group, based in Hong Kong. Prior to joining PJT Partners, Ms. Chow spent 14 years at Morgan Stanley, where she leads Greater China financial sponsors coverage for the Investment Banking Division. She is experienced across secondary advisory, M&A, equity and debt financing in Asia Pacific.

Ms. Chow received an MBA from Harvard Business School, and a BA with distinction from Yale University in Economics and International Studies.

Ping Zhou Co-Managing Editor, APAC DEBTWIRE

Ping Zhou leads a China journalists team writing distressed and event-driven corporate credits for Asia high yield fix income investors and restructuring advisories, covering both onshore and offshore Chinese restructuring and liquidation situations for Debtwire APAC since 2013. She started her journalist career with Financial Times in 2011 and won SOPA 2012 award in Hong Kong for breaking news on Wukan Guangdong protests. She has Korean literature background and lived in Pyongyang, Seoul, before moving to Hong Kong.

Simon Chan Director BLACKROCK

Simon Chan, Director, is part of the Asia Pacific Private Credit team, focusing on sourcing, evaluating, and executing private credit opportunities primarily in Greater China.

Prior to joining BlackRock, Simon was at Sixth Street Partners, investing across Strategic Capital opportunities and Special Situations strategies. Simon started his finance career as an investment banking analyst at the M&A team of UBS, based in Hong Kong.

Simon received a master's degree in computer science from the University of Pennsylvania and a bachelor's degree in business administration from the Ross School of Business, University of Michigan.

Tim Tu Managing Director, Head of APAC Corporate Book in Global Lending Unit UBS

Tim Tu is the Head of APAC Corporate Book in the Global Lending Unit at UBS. He was previously the Co-Head of the Asia Pacific Financing Group (AFG) and the Head of AFG, Greater China at Credit Suisse. 

Mr. Tu held the position as the CEO of Credit Suisse Securities (China) Limited (CSS), the bank’s majority-owned securities joint venture in China, until April 2022. As CEO of the securities joint venture, he was responsible for leading and managing the joint venture's overall strategy and business operations, in alignment with Credit Suisse’s broader Greater China strategy

严 莹莹 董事总经理 顺朋投资

华中科技大学数量经济学博士，中南财经政法大学校外硕士研究生导师。严博士在房地产收并购、特殊机会投资、地产基金、资产证券化等领域有着丰富的投融资经验，为LP带来了丰厚的投资回报。在加入顺朋投资之前，严博士曾服务于中国建设银行总行、碧桂园集团（联席总裁助理），帕拉丁资产业务总裁，严博士也担任英国伦敦Grand Central Apartments项目董事。——改为：严博士曾服务于中国建设银行总行、碧桂园集团（联席总裁助理）以及帕拉丁资产（业务总裁），同时也担任英国伦敦Grand Central Apartments项目董事。

杨 李 合伙人 汉坤律师事务所

Leigh is a partner with Han Kun’s Investment Fund Group, and her practice primarily focuses on investment fund formation, asset management, and foreign direct investment. She has over ten years of experience in the industry and worked closely with many of the most active PE/VC fund managers and asset allocators in Greater China. She is exceptionally well versed in handling cross-border fund formation matters (e.g., QFLP, QDLP/QDIE, QFII, QDII). She closely monitors the development of China’s foreign exchange administration policies and is also a zealous advocate for developing China’s PE/VC secondary market.

Leigh graduated from Sun Yat-sen University (SYSU) with an LL.B. degree in 2008. She also received a Master of Commercial Laws degree from Seoul National University and an LL.M. degree from Columbia Law School (with honors). Before joining Han Kun, Leigh worked at King & Wood Mallesons (Guangzhou and Beijing offices) and Kim & Chang (Seoul office).

Leigh is a native Chinese Mandarin speaker, and she is also fluent in English, Korean, and several Chinese dialects (e.g., Cantonese and Sichuanese).

Joyce Zhang Senior Investment Officer WALLACE

Joyce Zhang joined the investment team at Wallace in 2016. She assists the chief investment officer in the management of the foundation’s investment portfolio. Her responsibilities include the monitoring of investment managers, and risk management and analytical support.

Zhang worked as a senior fixed income trader at Ping An Asset Management, one of the largest insurance companies in China.

Zhang received her M.B.A. from Yale University. She holds an M.S. in global business from Pepperdine University and a B.S. in electrical engineering from Sun Yat-sen University in Guangzhou, China. Zhang is both a chartered financial analyst (CFA) and chartered alternative investment analyst (CAIA).

郭 伊扬 合伙人 雅登投资

Doris (Partner) is responsible for all aspects of the primary investment process, including fund selection, due diligence, negotiations, monitoring, and general partner relationship management within China.

Prior to joining Adams Street, she was a Senior Associate for Adveq Investment Management Co. Ltd., a global private equity firm, responsible for sourcing and executing growth/buyout funds and secondary investments in China and Japan. Prior to Adveq, she focused on direct investment activity for C.V. Starr Investment Advisory Asia Ltd.

Doris was named one of Private Equity International (PEI)’s 40 under 40: Future Leaders of Private Equity.

Ronald Liu Managing Director, China TEMASEK

Ronald Liu joined Temasek in June 2019 and is currently Managing Director, China. Hei s responsible for Temasek’s Financial Services, Consumer and Fund investments in China.